GLUE Stock — Monte Rosa Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company developing a portfolio of novel and proprietary molecular glue degraders, or MGDs. MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins, in effect editing the human proteome.

Source: 10-K FY2025 via SEC EDGAR

Share price

$10.57

Market cap

$901.8M

Cash

$577.7M

Enterprise value

$324.1M

Balance sheet

Cash	$577.7M
Debt	$0.0M
Net cash	$577.7M
Enterprise value	$324.1M
Basic shares	85.5M shares
Fully diluted shares	121.0M shares
Fully diluted market cap	$1,278.9M
Cash per share	$6.76
Quarterly burn	$44.1M
Cash runway	14.1 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

85.3M

Pre-funded warrants

16.5M

Options

15.9M

RSUs

1.2M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.1M

FDSO

121.0M

Cap table as of 2026-07-31.

Price history

Loading GLUE daily closes…

Loading price history…

Next catalyst

second-generation NEK7-directed molecular glue degrader · Est. Nov 7, 2026 · half midpoint · guided Now

Recently reported

MRT-8102 Phase 1 Positive · 2026-10-01

GFORCE-1 · healthy volunteers, elevated crp

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now half midpoint	second-generation NEK7-directed molecular glue degrader	Not disclosed	Not disclosed	H2 2026
GUIDEDDec 1-31 in 24d	MRT-2359 Phase 1/2 expansion arm with enzalutamide in advanced CRPC	Phase 1/2	advanced CRPC	by the end of 2026
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	cyclin E1-directed molecular glue degrader	Not disclosed	Not disclosed	2027
Nov 12 - Dec 24 in 12 mo	Oral MRT-2359	Phase 2	Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

MRT-2359

Stage not disclosed · Active Modality: molecular glue degrader

Target GSPT1

Indications

NSCLC (Phase 2)
SCLC (Phase 2)
High Grade Neuroendocrine Cancer (Phase 2)

Status note GSPT1-directed MGD; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.

MRT-8102

Stage not disclosed · Active Modality: molecular glue degrader

Target NEK7

Indications

not disclosed (Stage not disclosed)

Status note NEK7-directed MGD; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.

MRT-6160

Stage not disclosed · Active Modality: molecular glue degrader

Target VAV1

Partnerships Novartis: license agreement (2024) for MRT-6160 and other discovery programs

Indications

not disclosed (Stage not disclosed)

Status note VAV1-directed MGD out-licensed to Novartis; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Oral MRT-2359
Lead indication	NSCLC
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07745361	Phase 2	Recruiting	Sponsor	GLUE	—	Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer	by the end of 2026
NCT05546268	Phase 2	Active, not recruiting	Sponsor	GLUE	—	NSCLC; SCLC; High Grade Neuroendocrine Cancer	—
NCT07119125	Phase 1	Active, not recruiting	Sponsor	GLUE	—	Healthy Volunteers; Elevated CRP	H2 2026 Est. Nov 7, 2026 · half midpoint

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Monte Rosa Therapeutics, Inc on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
BVF Partners	4,460,886	no change	2.76%	2026-08-14
Baker Bros. Advisors	4,345,736	no change	0.53%	2026-08-14
Braidwell LP	2,451,562	-755,012	2.19%	2026-08-14
Aisling Capital	1,555,664	no change	7.98%	2026-08-13
Frazier Life Sciences	1,000,000	no change	0.53%	2026-08-14
ADAR1 Capital Management	216,752	+1,000	0.25%	2026-08-14
Casdin Capital	186,014	no change	0.23%	2026-08-14
Cormorant Asset Management	0	-400,000	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

GLUE — Monte Rosa Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

GLUE — Monte Rosa Therapeutics Inc.